Diabetes and ADHD drugs to be tested on Alzheimer's patients in new study

The United Kingdom has launched a clinical trial that will test drugs traditionally used for diabetes and attention‑deficit hyperactivity disorder in patients with Alzheimer’s disease. The effort is described as pioneering and seeks disease‑modifying treatments. Multiple outlets have reported on the initiative. The BBC emphasized the repurposing of diabetes and ADHD medications as the core intervention. SussexWorld noted that the Tangmere dementia charity welcomed the national research funding that underpins the work and urged additional support for local families.

The MP’s statement was also reproduced, underscoring the political dimension. Alzheimer’s disease remains the leading cause of dementia worldwide, yet no therapy has yet demonstrated a clear ability to halt neurodegeneration. Conventional drug development cycles often span many years, slowing the introduction of new medicines. Researchers have therefore turned to drug repurposing, testing agents with established safety profiles—such as those for type‑2 diabetes and ADHD—in hopes of identifying neuroprotective effects more quickly. Recent increases in UK dementia‑related research funding and a national dementia strategy provide the financial and policy framework that makes the current trial feasible.

Future coverage will monitor the trial’s enrolment milestones, regulatory clearances and any interim data releases. Observers will also watch for further statements from Toby Perkins or other policymakers that could shape additional funding streams or care‑service reforms. If early results suggest efficacy, the study could prompt broader clinical testing of repurposed drugs and influence the design of subsequent Alzheimer’s trials across Europe.